Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free GENF Stock Alerts

Genflow Biosciences (GENF) Competitors

Genflow Biosciences logo
GBX 2.25 +0.05 (+2.27%)
As of 11:55 AM Eastern
Compare

GENF vs. COIL, COS, SAR, C4XD, and DDDD

Should you buy Genflow Biosciences stock or one of its competitors? MarketBeat compares Genflow Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genflow Biosciences include Roquefort Therapeutics (COIL), Collagen Solutions plc (COS.L) (COS), Sareum (SAR), C4X Discovery (C4XD), and 4D pharma (DDDD). These companies are all part of the "biotechnology" industry.

How does Genflow Biosciences compare to Roquefort Therapeutics?

Genflow Biosciences (LON:GENF) and Roquefort Therapeutics (LON:COIL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Genflow Biosciences is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A

In the previous week, Genflow Biosciences had 2 more articles in the media than Roquefort Therapeutics. MarketBeat recorded 2 mentions for Genflow Biosciences and 0 mentions for Roquefort Therapeutics. Genflow Biosciences' average media sentiment score of 0.16 beat Roquefort Therapeutics' score of 0.00 indicating that Genflow Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Genflow Biosciences Neutral
Roquefort Therapeutics Neutral

Genflow Biosciences has a net margin of 840.76% compared to Roquefort Therapeutics' net margin of -57,057.07%. Genflow Biosciences' return on equity of 377.33% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences840.76% 377.33% -58.66%
Roquefort Therapeutics -57,057.07%-18.30%-15.86%

0.1% of Genflow Biosciences shares are owned by institutional investors. Comparatively, 1.2% of Roquefort Therapeutics shares are owned by institutional investors. 25.8% of Genflow Biosciences shares are owned by company insiders. Comparatively, 36.2% of Roquefort Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Genflow Biosciences has a beta of 2.306, meaning that its stock price is 131% more volatile than the broader market. Comparatively, Roquefort Therapeutics has a beta of 0.05, meaning that its stock price is 95% less volatile than the broader market.

Summary

Genflow Biosciences beats Roquefort Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Genflow Biosciences compare to Collagen Solutions plc (COS.L)?

Genflow Biosciences (LON:GENF) and Collagen Solutions plc (COS.L) (LON:COS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Collagen Solutions plc (COS.L) has higher revenue and earnings than Genflow Biosciences. Genflow Biosciences is trading at a lower price-to-earnings ratio than Collagen Solutions plc (COS.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
Collagen Solutions plc (COS.L)£4.01M0.00N/A-£0.80N/A

0.1% of Genflow Biosciences shares are held by institutional investors. 25.8% of Genflow Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Genflow Biosciences had 2 more articles in the media than Collagen Solutions plc (COS.L). MarketBeat recorded 2 mentions for Genflow Biosciences and 0 mentions for Collagen Solutions plc (COS.L). Genflow Biosciences' average media sentiment score of 0.16 beat Collagen Solutions plc (COS.L)'s score of 0.00 indicating that Genflow Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Genflow Biosciences Neutral
Collagen Solutions plc (COS.L) Neutral

Genflow Biosciences has a net margin of 840.76% compared to Collagen Solutions plc (COS.L)'s net margin of 0.00%. Genflow Biosciences' return on equity of 377.33% beat Collagen Solutions plc (COS.L)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences840.76% 377.33% -58.66%
Collagen Solutions plc (COS.L) N/A N/A N/A

Summary

Genflow Biosciences beats Collagen Solutions plc (COS.L) on 8 of the 10 factors compared between the two stocks.

How does Genflow Biosciences compare to Sareum?

Genflow Biosciences (LON:GENF) and Sareum (LON:SAR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Genflow Biosciences is trading at a lower price-to-earnings ratio than Sareum, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
SareumN/AN/A-£5.28M-£3.90N/A

In the previous week, Genflow Biosciences had 2 more articles in the media than Sareum. MarketBeat recorded 2 mentions for Genflow Biosciences and 0 mentions for Sareum. Genflow Biosciences' average media sentiment score of 0.16 beat Sareum's score of 0.00 indicating that Genflow Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Genflow Biosciences Neutral
Sareum Neutral

Genflow Biosciences has a beta of 2.306, meaning that its share price is 131% more volatile than the broader market. Comparatively, Sareum has a beta of -1.08, meaning that its share price is 208% less volatile than the broader market.

Genflow Biosciences has a net margin of 840.76% compared to Sareum's net margin of 0.00%. Genflow Biosciences' return on equity of 377.33% beat Sareum's return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences840.76% 377.33% -58.66%
Sareum N/A -284.01%-113.80%

0.1% of Genflow Biosciences shares are owned by institutional investors. 25.8% of Genflow Biosciences shares are owned by insiders. Comparatively, 35.7% of Sareum shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Genflow Biosciences beats Sareum on 9 of the 11 factors compared between the two stocks.

How does Genflow Biosciences compare to C4X Discovery?

C4X Discovery (LON:C4XD) and Genflow Biosciences (LON:GENF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

C4X Discovery has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.306, suggesting that its stock price is 131% more volatile than the broader market.

52.1% of C4X Discovery shares are held by institutional investors. Comparatively, 0.1% of Genflow Biosciences shares are held by institutional investors. 27.1% of C4X Discovery shares are held by company insiders. Comparatively, 25.8% of Genflow Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Genflow Biosciences had 2 more articles in the media than C4X Discovery. MarketBeat recorded 2 mentions for Genflow Biosciences and 0 mentions for C4X Discovery. Genflow Biosciences' average media sentiment score of 0.16 beat C4X Discovery's score of 0.00 indicating that Genflow Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
C4X Discovery Neutral
Genflow Biosciences Neutral

Genflow Biosciences has a net margin of 840.76% compared to C4X Discovery's net margin of 42.81%. Genflow Biosciences' return on equity of 377.33% beat C4X Discovery's return on equity.

Company Net Margins Return on Equity Return on Assets
C4X Discovery42.81% 55.38% 28.04%
Genflow Biosciences 840.76%377.33%-58.66%

C4X Discovery has higher revenue and earnings than Genflow Biosciences. Genflow Biosciences is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
C4X Discovery£24.68M0.00£10.57M£0.04N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

Summary

C4X Discovery beats Genflow Biosciences on 7 of the 12 factors compared between the two stocks.

How does Genflow Biosciences compare to 4D pharma?

Genflow Biosciences (LON:GENF) and 4D pharma (LON:DDDD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

0.1% of Genflow Biosciences shares are held by institutional investors. Comparatively, 26.8% of 4D pharma shares are held by institutional investors. 25.8% of Genflow Biosciences shares are held by company insiders. Comparatively, 12.2% of 4D pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Genflow Biosciences has a beta of 2.306, suggesting that its share price is 131% more volatile than the broader market. Comparatively, 4D pharma has a beta of 2.63, suggesting that its share price is 163% more volatile than the broader market.

In the previous week, Genflow Biosciences had 2 more articles in the media than 4D pharma. MarketBeat recorded 2 mentions for Genflow Biosciences and 0 mentions for 4D pharma. Genflow Biosciences' average media sentiment score of 0.16 beat 4D pharma's score of 0.00 indicating that Genflow Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Genflow Biosciences Neutral
4D pharma Neutral

Genflow Biosciences has higher earnings, but lower revenue than 4D pharma. Genflow Biosciences is trading at a lower price-to-earnings ratio than 4D pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
4D pharma£718K0.00-£31.94M-£15.40N/A

Genflow Biosciences has a net margin of 840.76% compared to 4D pharma's net margin of 0.00%. Genflow Biosciences' return on equity of 377.33% beat 4D pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences840.76% 377.33% -58.66%
4D pharma N/A -89.48%-42.64%

Summary

Genflow Biosciences beats 4D pharma on 7 of the 12 factors compared between the two stocks.

Get Genflow Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GENF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GENF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

GENF vs. The Competition

Export
MetricGenflow BiosciencesBiotechnology IndustryMedical SectorLON Exchange
Market Cap£12.74M£508.45M£6.85B£2.78B
Dividend YieldN/A3.87%2.66%6.14%
P/E Ratio-6.783.1126.04366.54
Price / SalesN/A6,785.72550.1785,951.69
Price / Cash3.0013.1329.0927.87
Price / Book9.0789.3710.987.75
Net Income-£1.76M-£96.07M£3.57B£5.89B
7 Day Performance5.19%1.23%3.06%-1.01%
1 Month Performance7.14%-0.19%0.72%-1.74%
1 Year Performance212.50%74.49%36.82%65.54%

Genflow Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GENF
Genflow Biosciences
N/AGBX 2.25
+2.3%		N/A+209.0%£12.74MN/AN/A5
COIL
Roquefort Therapeutics
N/AGBX 11
+10.0%		N/A-25.9%£46.95MN/AN/A9
COS
Collagen Solutions plc (COS.L)
N/AN/AN/AN/A£30.99M£4.01MN/A3,350
SAR
Sareum
N/AGBX 22.04
-4.2%		N/A+51.7%£30.54MN/AN/A3,211
C4XD
C4X Discovery
N/AN/AN/AN/A£30.27M£24.68M300.0049

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:GENF) was last updated on 6/29/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SpaceX is offering you shares. Don't take them.
SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...
Behind the Markets | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel